1620555-86-3

Upstream product

• 1620555-85-2 (1R,2S,5R,6R,Z)-3-(benzoyloxyimino)-5-(tert-butoxycarbonylamino)-7-oxabicyclo[4.1.0]heptan-2-ylbenzoate 
• 1620555-84-1 1S,4R-(5-hydroxy-4-hydroxyimino-7-oxabicyclo[4.1.0]hept-2-yl)carbamic acid tert-butyl ester 
• 77300-23-3 cyclohex-(±)-(1R*,4S*)-2-ene-1,4-diyl dibenzoate 
• 1620555-94-3 1S,4R-(5-hydroxy-7-oxa-bicyclo[4.1.0]hept-2-yl)carbamic acid tert-butyl ester 
• 1620555-83-0 (4-hydroxyimino-5-oxo-7-oxabicyclo[4.1.0]hept-2-yl)carbamic acid tert-butyl ester 
• 217438-72-7 1R,4S-(4-hydroxycyclohex-2-enyl)carbamic acid tert-butyl ester 
• 1620555-82-9 1S,4R-(5-oxo-7-oxabicyclo[4.1.0]hept-2-yl)carbamic acid tert-butyl ester 

Downstream Products

• 1620561-13-8 (1R,2R,3S,4S,5S)-5-benzamido-2,3,4-trihydroxycyclohexanaminium 2,2,2-trifluoroacetate 

Relevant academic research and scientific papers

Asymmetric stereodivergent strategy towards aminocyclitols

A concise asymmetric synthesis of aminocyclitols, such as diastereomeric 2-deoxystreptamine analogues and conduramine A, is described. The Pd-catalyzed asymmetric desymmetrization of meso 1,4-dibenzolate enables the synthesis of highly oxidized cyclohexane architectures. These scaffolds can potentially be used to access new aminoglycoside antibiotics and enantiomerically pure α-glucosidase inhibitors.